Introduction
Thioredoxin-1 (Trx-1) is a ubiquitously expressed 105 amino acid redox protein found in the cytoplasm and nucleus. Trx-1 undergoes reversible NADPH-dependent reduction by thioredoxin reductases [1] [2] [3] [4] . Trx-1 transfection of cancer cells stimulates tumor growth [5] and inhibits both spontaneous and drug induced apoptosis [6] . Transfection with a redox inactive mutant Trx-1 fails to transform the cells, inhibits cell growth, potentiates apoptosis [5, 7] and blocks tumor formation by the cells in immunodeficient scid mice [6] . Trx-1 regulates several transcription factors including NF-κB, glucocorticoid receptor, AP-1, and HIF-1α [4, [8] [9] [10] . Trx-1 over-expression increases VEGF production and stimulates neoangiogenesis, primarily via up-regulation of HIF-1α [11] . Trx-1 is also secreted by cancer cells wherein it has growth promoting properties [12] . Intracellular Trx-1 protein levels are significantly elevated in human gastrointestinal cancers including 50% of gastric cancer cases [3] , 55% of colorectal cancers [13] and 41% of pancreatic cancer [14, 15] . Increased Trx-1 expression in colon cancer is an independent prognostic factor for decreased patient survival [13] . Elevation of plasma Trx-1 has also been reported in pancreatic and hepatocellular cancers [15, 16] .
PX-12 (1-methylproply 2-imidazolyl disulfide) is a novel small molecule inhibitor of Trx-1. The inhibitory action of PX-12 is primarily due to the irreversible thioalkylation of Trx-1 on its Cys73 residue in the non-catalytic domain [17] . PX-12 has also been shown to inhibit tubulin polymerization through cysteine oxidation [18] . PX-12 treatment results in anti-tumor activity in a variety of pre-clinical models, including the HT-29 human colon cancer cell line and is associated with a decrease in HIF-1α and VEGF expression [19] . Consistent with this observation, pre-clinical investigations in HT-29 xenograft tumors demonstrated that PX-12 treatment caused a rapid 63% decrease in the average tumor microvascular permeability, measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), within 2 h of drug administration. The decrease lasted 24 h and returned to pretreatment values by 48 h post-drug [20] .
FGF-2 is an growth factor that can regulate a variety of activities including angiogenesis. FGF-2 can act synergistically with VEGF, and has been implicated in mediating resistance to anti-VEGF therapies [reviewed by [21] ]. In a human microvascular endothelial cell (HMVEC) migration model, exogenous treatment with FGF-2 resulted in induction of thioredoxin interacting protein (TXNIP), a negative regulator of Trx-1. Further studies in this model demonstrate that FGF-2 treatment results in increased Trx-1 activity, and that repression of TXNIP with siRNA was sufficient to stimulate HMVEC migration [22] . Exogenous FGF-2-2 has recently been reported to induce the expression of Trx-1 in lung cancer cell lines [23] . Together, these observations suggest that Trx-1 may exert some of its angiogenic activity via the FGF-2 pathway.
PX-12 has undergone early Phase 1 clinical testing in patients with various solid tumors [24] , with the dose limiting toxicity being reversible chemical pneumonitis that occurred at a dose of 300 mg/m 2 . Based on pharmacokinetic data and the observation that decreases in circulating Trx-1 levels were more pronounced after a 3 h infusion compared to a 1 h infusion, it was felt that prolongation of PX-12 infusion time may provide additional therapeutic benefit and improve tolerability. In a subsequent Phase 2 study of a 3-hours infusion every day for 5 days every 21 days was administered to patients with advanced cancer of the pancreas. This study was discontinued before an MTD was established for several reasons. These included an unexpectedly low level of circulating Trx-1, lack of significant antitumor activity, and toxicity, manifested as a cough and odor associated with the expired metabolite 2-butanethiol. A second Phase 1 trial of PX-12 investigated a 72-hour infusion every 21 days in 14 patients with advanced solid cancers. The longer infusion time was associated with less odor and cough, but demonstrated limited clinical benefit. The best response was stable disease in a patient with rectal cancer [35] .
Based on these results, we conducted a Phase IB trial of PX-12 in patients with advanced gastrointestinal tumor. The goal was to determine the maximally tolerated dose (MTD) of PX-12 delivered as a 24-hour infusion repeated every 7 or every 14 days. The secondary objectives were to assess pharmacokinetics, pharmacodynamics, and the efficacy of PX-12. The pharmacodynamic endpoints included dynamiccontrast-enhanced magnetic resonance imaging (DCE-MRI), pre-and post-dose drug administration in order to evaluate the effect of PX-12 on tumor perfusion and vascular permeability and plasma Trx-1, VEGF, and FGF-2 levels at baseline, and at the end of each treatment cycle.
Patients and methods

Patient selection
Eligible patients were over 18 years of age with pathologically confirmed diagnosis of advanced or metastatic gastrointestinal (colorectal, gastroesophageal or pancreaticobiliary) cancer refractory to standard therapies. Other major criteria were: predicted life expectancy of at least 12 weeks, performance status of 0-2 Eastern Cooperative Oncology Group (ECOG), and no anticancer therapy or other investigational agent(s) for at least 4 weeks prior to study registration (6 weeks for mitomycin C or nitrosureas). Patients had discontinued radiation therapy for at least 4 weeks prior to entry into the study and must have recovered (grade 1 or less) from all radiation-related toxicities. Adequate organ function was defined by WBC count >2,500 cells/μl, platelets >100,000/μl, hemoglobin >9 g/dL (may be transfused to this level), and an ANC >1500 cells/μl. Other laboratory requirements included creatinine <2.0 mg/dL, bilirubin <2.0 mg/dL, aspartate transaminase (AST/SGOT) and alanine transaminase (ALT) <3 times institutional upper limit of normal (ULN) or <5 times institutional ULN if the subject has documented liver metastases and international Normalized Ratio (INR) and activated partial thromboplastin time (PTT) within 1.5 times ULN unless subject was on prophylactic warfarin.
Patients were excluded from the study if they were pregnant or lactating, had any serious concomitant systemic disorders that in the opinion of the investigator would place the patient at excessive or unacceptable risk of toxicity or had surgery within 4 weeks of study entry. Other exclusion criteria were, a history of seizures, any untreated brain metastasis, unstable arrhythmias requiring control by medication, ischemic event experienced within the preceding 6 months, prior history of congestive heart failure requiring therapy, active infection requiring parenteral antibiotics at study entry, active (requiring continuous medical therapy) pulmonary disease (COPD, asthma) or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest Xray or chest CT scan, any active secondary malignancy diagnosed within the last 2 years, or inability to tolerate prophylactic (1 mg/day) warfarin.
Written informed consent was obtained from all patients before entering the study.
Study design
This was a Phase IB dose escalation study to establish the MTD of PX-12 administered every 14 days. PX-12 was administered via a 24-hour infusion through a central venous catheter utilizing an infusion pump, on Day 1 of each 14-day cycle. Due to concern with local phlebitis observed in animal studies, patients also received a prophylactic dose of warfarin 1 mg/day. PX-12 dose started at 150 mg/m 2 and escalated to 200, 300, 400 and 450 mg/m 2 in cohorts of 3 patients per dose level. A standard "3+3" design was used. If one of three patients experienced dose limited toxicity (DLT), the cohort expanded to six patients. If there was no DLT, the dose was escalated to next cohort of three patients. If 2 DLT occurred at a dose level, then the previous dose was considered the MTD and dose escalation terminated. When the 14-day bi-weekly dosing cycle reached 450 mg/m 2 patient without evidence of drug accumulation or DLT's, the schedule was modified to evaluate cohorts on a weekly dosing schedule, starting at a lower dose level of 300 mg/m 2 of PX-12.
Drug administration PX-12 was diluted with 5% dextrose solution, filtered, and administered using a portable ambulatory infusion device over 24 h to allow outpatient treatment.
Safety assessments
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria CTCAE version 3.0. Dose-limiting toxicity (DLT) was defined as any of the following events related to PX-12 during the first treatment cycle (14 days): grade 4 hematologic toxicity or grade 3 or greater nonhematologic toxicity. The occurrence of a DLT or failure to recover to grade 1 within 2 weeks required patients to be removed from study. Patients who recovered to grade 1 or lower toxicity continued at the next lowest dose level or at 50% of the previous dose as long as their disease continued to be stable or responding.
In addition, a delay in the scheduled treatment for more than 14 days due to ongoing treatment related toxicity was considered as a DLT. Patients receiving PX-12 in cycle 2 and beyond for bi-weekly and weekly dosing schedules with stable or responding disease who experienced DLT had their therapy held until their toxicity improved to grade 1 or less. Following this, therapy with PX-12 was continued at the next lower dose level. Any patient experiencing a second DLT at the lower dose was removed from study.
Pharmacokinetic analysis
Plasma was collected at pre-dose and end of the infusion for the first four cycles for pharmacokinetic analysis. For the biweekly schedule, plasma was also collected at 3 and 6 h after the start of the first infusion. Plasma PX-12 concentrations were measured using liquid chromatography in tandem with mass spectrometry (LC-MS). Calibration curves were prepared in PBS for quantitative analysis because of the varying extents of interaction between PX-12 with human plasma obtained from different sources. Each calibration PBS standard or plasma sample was mixed with five volumes of acetonitrile. An aliquot of the supernatant was injected onto the LC-MS system. The chromatographic separation was achieved on a Hypercarb column (100×4.6 mm) with a gradient mobile phase consisting of 20 mM ammonium acetate and acetonitrile. PX-12 was detected by multiple reaction monitoring with electrospray ionization in the positive mode. Linearity was established over the concentration range of 1-50 ng/ml. The reported plasma PX-12 levels represent the non-covalently bound PX-12 or PX-12 that has not undergone the thiol/disulfide exchange. Plasma concentrations of the primary metabolite 2-mercapto imidazole (2-MI) in the end of infusion samples were measured as described previously [24] .
Plasma biomarker assessment
Normal donor blood samples were collected in heparinized tubes by the Red Cross or purchased from Bioreclamation Inc (City, State). The plasma was separated and stored at −70°C until analyzed. Patient plasma was isolated from whole blood collected in heparin coated tubes. Blood was centrifuged for 15 min at 1500×g at room temperature to sediment platelets and particulate matter. Plasma was aliquoted and frozen at −80°C until analyzed. Plasma samples for Trx-1, VEGF and FGF-2 protein level analysis were collected prior to study drug administration on day 1 and then 3 h, 6 h, and at the end of the infusion (24 h) from the start of infusion in the first cycle. For three cycles thereafter plasma samples were taken prior to the infusion and at the end of the 24 h infusion. The concentration of Trx-1 was measured as reported previously [25] . The concentration of FGF-2-2, and VEGF was measured according to the protocol provided in R&D Systems (Minneapolis, MN) Human VEGF Quantikine ELISA Kit and Human FGF basic Quantikine HS ELISA Kit. All samples from each patient were analyzed together on one ELISA plate for each analyte (Trx-1, VEGF, FGF-2) in order to minimize day to day and plate to plate variation. Any sample with higher than 20% CV within triplicates was re-tested. Positive controls were run on each plate to ensure reproducibility between run days and reagent lots. Plasma samples were assessed for hemolysis to ensure analyte levels were not affected due to red cell lysis during sample processing.
Dynamic contrast-enhanced MRI DCE-MRI was performed on a 1.5 T MRI scanner (GE) using an 8 channel phased-array coil (GE). DCE-MRI data were collected from subjects who repeated a "breathe-in, breathe-out and hold" pattern, with the imaging occurring during each held-expiration period. Prior to the dynamic portion of the scanning, four precontrast Three Dimensional Gradient Recalled Echo (3D-GRE) images were obtained at flip angles of 15°, 23°, 30°and 60°so that a pre-contrast T1 map could be calculated in each case. The dynamic series portion of the imaging comprised of 24-30 3D-GRE images collected during repeated "held exhalation" breath-holds. This afforded a temporal resolution of 16-18 s in the DCE-MRI series. Parameters for the 3D-GRE imaging were, 12 slices reconstructed to a matrix size of 256× 256, slice thickness05 mm, TR05.0 ms, TE02.1 ms, and α 030°. After 1-2 pre-contrast images had been acquired as a baseline and to ensure adequate image quality, gadolinium contrast (Omniscan®, GE Healthcare) was injected at a dose of 0.1 mmol/kg at a rate of 4 ml/s using a power injector (Mallinckrodt Cincinnati, OH), and chased with a 20-ml saline flush also injected at 4 mL/s. Pixel-by-pixel pharmacokinetic analysis of DCE-MRI data was performed using a twocompartment model [26] . Prior to pharmacokinetic analysis, sequential elastic registration was performed on the DCE-MRI images to reduce misregistration arising from inconsistent breathholding, as described previously [27] . Three physiologically relevant parameters were calculated for each pixel, the volume transfer constant (K trans ), volume fraction of the extravascular extracellular space (v e ), and plasma volume fraction (v p ), by fitting image data to the following equation:
where C p (t) is the arterial input function (AIF) calculated from a region-of-interest (ROI) placed over the descending aorta, and C t (t) is the volume-averaged concentration of the contrast agent in a pixel. C t (t) was calculated assuming a linear dependence of signal enhancement on the concentration of contrast agent, from the known in vitro longitudinal relaxivity of the contrast agent.
Efficacy assessment
Tumor assessments were performed within 1 week preceding PX-12 dosing and every 4th cycle (approximately every 8 weeks) until disease progression or study discontinuation.
Results
Patient characteristics
Eighteen patients were enrolled at Arizona Cancer Center, Tucson, AZ. All patients received at least one dose of PX-12. Patient characteristics are summarized in Table 1 .
Treatment administration
The median time on study was 4 cycles or 8 weeks of therapy (Table 2) . Five patients completed 4 cycles, four patients completed 2 cycles, four patients completed 1 cycle (all of them on a weekly schedule), three patients completed 3 cycles (one of which had weekly cycles), one patient completed 5 cycles and one completed 8 cycles. The reason for treatment discontinuation was progressive disease (PD) in 8 patients, adverse event in 2 patients, and death in 1 patient. Toxicity Treatment-emergent toxicities are summarized in Table 3 . The only true dose -limiting toxicity (DLT), defined as occurring within first cycle of therapy was observed at a dose level of 400 mg/m 2 . This involved grade 3 hyperbilirubinemia 3 days after the second dose in the first cycle, with resolution after 24 h. The same patient also had grade 3 fatigue and elevated serum alkaline phosphatase after the second dose of the first. Several patients experienced grade 3 or 4 toxicities beyond the first cycle of therapy. One of three patients at dose 150 mg/m 2 had a grade 3 fatigue after the fourth cycle. One of four patients at dose level 200 mg/m 2 developed a grade 3 pneumonia after the second cycle of study drug. Two of six patients at dose level 300 mg/m 2 (both of them received a weekly schedule) had grade 3 toxicity. One of these patients had a grade 3 cough, shortness of breath, hyponatremia, and hypoalbuminemia after the second cycle. The other patient at this dose level had grade 3 hyperbilirubinemia and elevated serum alkaline phosphatase after the third cycle (related to biliary tract obstruction from cancer). Two of three patients at the 450 mg/m 2 dose level developed grade 3 toxicities. One developed grade 3 fatigue, nausea, vomiting and small bowel obstruction 21 days after the second cycle of the study drug and was then excluded from the study due to disease progression. The second patient at this dose level developed grade 3 small bowel obstruction, hypotension, and elevated INR following the third cycle.
Hematologic toxicity was uncommon, with only two of nineteen patients exhibiting grade 2 hematologic adverse events, one patient having anemia and the other patient having elevated prothrombin time. Another patient had grade 3 elevation of prothrombin time.
The most common non-hematologic toxicities were nausea, fever, vomiting, ascites, diarrhea, fatigue, garlic odor, sweating, weight loss, urinary tract infection, confusion, dysgeusia, constipation, abdominal distention, gastritis, anxiety, cold intolerance, flu like symptoms and cough. Most toxicities were grade 1 or 2.
Efficacy
There were no objective radiological responses based on the RECIST criteria. Two patients achieved apparent stable disease as their best response but only one stayed on study treatment longer than 4 months. Pharmacokinetic data Figure 1 illustrates the cycle 1 individual concentration-time data from the 300 mg/m 2 bi-weekly cohort. PX-12 levels increased during infusion and reached a maximum concentration at the end of infusion. The collection times were limited to allow for calculation of pharmacokinetic parameters. Table 4 summarizes the plasma PX-12 and 2-MI concentrations at the end of the first infusion. Plasma concentrations of PX-12 were in the low ng/ml concentration range and seemed to increase as the dose increased. Plasma 2-MI concentrations were much higher than those of PX-12 and were in the low μg/ml concentration range. Analysis of pre-and post-cycle PX-12 concentrations from six subjects treated with up to 4 cycles indicated no apparent changes in the end-of-infusion PX-12 concentrations at different cycles.
Plasma pharmacodynamic data
Trx-1 plasma levels from frozen plasma of 89 healthy donors were measured via ELISA. The mean plasma Trx-1 level was 300mg/m2 every 2 weeks 6.6 +/− 3.8 ng/mL with a median value of 5.4 ng/mL and a range from 1.5 to 19.8 ng/mL (Fig. 2) . Increased plasma Trx-1 levels over the normal range were observed pretreatment in a sub-population of patients studied on this trial with concentrations ranging from 5.3 to 40.0 ng/mL (median017.4 ng/mL; mean 019.8 +/−1.4 ng/mL). A cut off of >18 ng/mL (approximately 3-fold mean normal levels) was selected to stratify the data from this patient population to determine if starting Trx-1 could predict response to PX-12 treatment. In the six patients treated with bi-weekly PX-12 (regardless of treatment dose) that had Trx-1 levels of >18 ng/mL prior to treatment there was a trend towards decreased plasma Trx-1 following PX-12 treatment over the first 4 cycles. Due to the small number of patients in the study, statistical significance was only observed at the EOI time point in cycle 1 (paired Student T test p00.03) (Fig. 3a) . Patients with Trx-1 levels under 18 ng/mL at the start of the study did not demonstrate a decrease in Trx-1 levels over the course of their treatment (Fig. 3b) . Two of the six patients (33%) whose plasma Trx-1 levels were lowered following PX-12 treatment achieved apparent Stable Disease (SD) and stayed on study over 4 cycles (02-00808 cycles, 02-00905 cycles).
No patients with pretreatment Trx-1 plasma levels under 18 ng/mL achieved SD on this study. The concentrations of Trx-1, FGF-2, and VEGF at baseline (pre-dose) are provided in Table 5 . The FGF-2 angiogenic factor was suppressed only in patients with PX-12-mediated decreases in Trx-1 levels. The two patients with apparent stable disease (subjects 02-008 and 02-009) had significantly lower plasma FGF-2 levels before cycle 3 (p0 0.03) and cycle 4 (p00.05) when compared to pre-treatment values by paired student T test analysis (Fig. 4) . VEGF levels, however, did not show any correlation with Trx-1 levels (data not shown) when stratified by Trx-1 pretreatment levels. Patients with stable disease did have minor decreases in plasma VEGF at the pre-dose cycle 3 (39% Overall, decreases in plasma Trx-1, VEGF or FGF-2 were not predictive of clinical benefit (apparent stable disease) to PX-12 in this study. Two patients with apparent stable disease lasting beyond 4 cycles did have decreases in all three of these analytes over the first 4 cycles of treatment. Due to the very small number of patients with apparent stable disease in this study, it is not possible to conclude whether these changes in phamacodynamic markers were mediated by PX-12 activity. Interestingly, the average plasma Trx-1 (19.8 +/−1.4 ng/mL) and VEGF levels (71.8 +/− 4.6 pg/mL) were higher in this patient group as compared to the patients enrolled on the 72-hour infusion Phase 1 study of PX-12 [28] . This observation supports prior studies demonstrating high cellular expression of Trx-1 in GI tumors.
DCE-MRI
DCE-MRI imaging was performed on 3 subjects (Table 6 ). Figure 5 depicts example K trans parameter maps calculated from a subject who received 400 mg/m 2 of the drug weekly by 24 h infusion. In subjects with multiple tumors, the target lesion was chosen based on size (largest) and location within the liver (right lobe, less affected by cardiac pulsatility). In subject 02-004, dosed at 200 mg/m 2 , no significant change in tumor K trans was measured 24 h following drug infusion. In subject 02-012, tumor K trans appeared to decrease 24 h following drug infusion at the 450 mg/m 2 dose level, rising back above baseline values by 7 days post-infusion. In subject 02-015, there was no significant change in tumor K trans 24 h following the first drug infusion at the 300 mg/m 2 dose level, but a decrease in tumor K trans relative to baseline was observed following the 2 nd of two biweekly infusions.
Discussion
PX-12 is the first targeted Trx-1 inhibitor to be investigated clinically. It has been evaluated in a total of four clinical trials. The current Phase 1B study in GI malignancies was designed for several reasons. The only minor response in the first Phase 1 trial of PX-12 was observed in a patient with appendiceal adenocarcinoma [24] , and the best clinical response in the second Phase 1 study investigating the 72-hour infusion was SD observed in a patient with rectal cancer [28] . Intracellular Trx-1 over-expression has been retrospectively correlated with advancing disease stage in colorectal cancers, and is associated with poorer survival [13] . In a separate study, intracellular Trx-1 expression in resected liver metastases has also been shown to be an independent prognostic factor for poor prognosis in patients with colorectal cancers [28] . Other gastrointestinal carcinomas have also been associated with Trx-1 levels. For example, intracellular Trx-1 protein has been reported to be overexpressed in gastric [3] and pancreatic cancers [29] .
In the current Phase 1B trial, a continuous 24 h infusion schedule was chosen because of better tolerance observed with longer infusions, defined by less respiratory irritation, cough, and pungent sulfur odor from 2-buthanethiol, an exhaled metabolite of PX-12. This study was designed to optimize a dosing schedule and infusion rate that would circumvent this problem and still provide sufficient drug exposure for anti-tumor activity. In this trial we were able to escalate the dose of PX-12 beyond 300 mg/m 2 without encountering pneumonitis, which was a DLT with previous explored one and 3-hour infusion schedules.
Despite the ability to deliver higher doses and the improved tolerability of the exhaled metabolite 2-buthanethiol, we did not seen any signs of objective anti-tumor activity. This lack of clinical activity could be due to failure to achieve optimal peak plasma concentrations of the parent PX-12 compound. In this study we measured the concentration of PX-12, as opposed to prior studies in which we were only able to detect 2-mercaptoimidazole [24] , which is one of the main metabolites. Due to the highly reactive nature of PX-12, we observed low ng/mL plasma concentrations of PX-12 with the presence of μg/mL concentration of the inactive metabolite 2-MI. This observation suggests that prolonged infusion schedules resulted in inadequate intra-tumoral peak exposure to the active agent.
DCE-MRI was included as one of the pharmacodynamic endpoints in this study based on pre-clinical data indicating that PX-12 treatment results in decrease in tumor microvascular permeability, consistent with inhibition of VEGF expression [20] . Only three patients were recruited to this optional portion of the study. Barriers to patient participation included patient anxiety associated with time in the scanner (approximately 30 min per scan) and difficulty in coordinating treatment administration with imaging time points. Interestingly, one patient with liver metastasis demonstrated a decrease in K trans 24 h post-treatment with 450 mg/m 2 PX-12, which was associated with a decrease in plasma VEGF levels from 19.3 pg/ml at baseline to 12.2 pg/ml at end of infusion.
Similar to prior studies with PX-12, there was a trend for patients starting with elevated plasma Trx-1 levels to have a reduction in Trx-1 plasma levels post-PX-12 treatment. Similarly, patients starting with the highest levels of FGF-2 had the greatest reductions in FGF-2 levels. Together, these observations suggest that PX-12 has some biological activity consistent with its reported mechanism of action in spite of the lack clinical activity observed in this study.
Given the lack of preliminary antitumor activity and an atypical toxicity profile (strong pungent odor, respiratory irritation and pneumonitis) it is difficult to propose further monotherapy studies with PX-12 in cancer patients. Nevertheless, because of mechanistic and translational studies, we believe that Trx-1 remains a target of interest for developing anti-cancer therapies. Several other thioredoxin-system inhibitors are in pre-clinical development. These include trans was low at baseline, decreasing at 24 h postinfusion, increasing above baseline by 7 days postinfusion. The color legend for K trans runs from 0.0 min −1 (dark blue) through 0.6 min −1 (yellow). K trans results for all study subjects are summarized in Table 5 PMX464, a thiol-reactive quinol, which inhibits Trx-1 function and has been shown to decrease proliferation and survival of HT-29 colon cancer cells, with enhanced activity in hypoxic conditions [30] . Ethaselen, an organoselenium compound, inhibits thioredoxin reductase and has been shown to decrease cell growth of the RTO colorectal cancer cell line [31] . These and other Trx system inhibitors may prove to be more clinically viable, and should be investigated in the setting of GI malignancies.
